For immediate release 07:00: 16 April 2015
HVIVO PLC
("hVIVO" or the "Company")
CONFIRMATION OF CHANGE OF NAME TO HVIVO PLC
Further to its announcement on 13 April 2015, the Company confirms that its name has now changed from Retroscreen Virology Group plc to hVIVO plc (AIM: HVO).
Trading in the Company's shares on AIM under its new name will take effect at 8.00am this morning.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 1950 volunteers for a range of leading industry, governmental and academic clients.
